Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Exploring Late Effects of Transplantation: Osteoporosis, Therapy-Related Leukemia

February 1, 1999
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 2
Volume 8
Issue 2

MIAMI BEACH-As more cancer patients undergo allogeneic and autologous peripheral blood stem cell (PBSC) and bone marrow transplants, more long-term complications crop up. Two papers presented at the ASH meeting addressed the late effects of reduced bone density and development of therapy-related leukemia.

MIAMI BEACH—As more cancer patients undergo allogeneic and autologous peripheral blood stem cell (PBSC) and bone marrow transplants, more long-term complications crop up. Two papers presented at the ASH meeting addressed the late effects of reduced bone density and development of therapy-related leukemia.

Bone density loss after solid tumor organ transplant has been documented, and is commonly related to pretransplant health status, organ dysfunction, and post-transplant immunosuppressive therapy. Likewise, cancer patients receiving PBSC or bone marrow transplants may face similar bone thinning.

Keith M. Sullivan, MD, and colleagues at the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, examined the incidence, severity, and onset of bone density abnormalities during the first year after allogeneic PBSC transplant.

Their longitudinal study measured bone density by dual energy x-ray absorptiometry (DEXA) at 3 and 12 months after transplant to determine the tempo and degree of bone density loss and its associated risk factors.

“We know very little about bone loss following stem cell transplant,” Dr. Sullivan commented, “and, with young adults, this will be an issue for their long-term survival.”

Dr. Sullivan reported results on 104 adults (52 women and 52 men), ranging in age from 18 to 66, without prior bone disease. DEXA scans of the hip at 3 months showed that 44% of the patients already had low bone density scores, and 4% of the patients had developed osteoporosis. In 35% of patients, the researchers observed low spine density (osteopenia); in 8% of patients they observed osteoporosis of the spine. “We found that the older the patient, the higher the risk for osteopenia,” Dr. Sullivan said. “There appeared to be no gender effect and no effect from use of total body irradiation.”

Also highly significant was cumulative prednisone use. Significant associations between chronic graft-versus-host disease and change in hip and spine density were presumably due to prednisone therapy, he said.

“We don’t yet know the most effective type and duration of routine preventive therapy,” Dr. Sullivan said, “but because osteopenia is so common after stem cell allografting, it is essential to prevent osteoporosis early after transplant. Future studies should carefully examine the value of interventions to minimize the risk of bone disease and later morbid-ity in these patients.”

Therapy-Related Leukemia

At the City of Hope National Medical Center, Duarte, Calif, A. Krishnan, MD, and colleagues focused on the risk factors for developing therapy-related leukemia (myelodysplasia or AML) after autologous transplantation for lymphoma.

“It’s not clear whether this well-known complication of therapy for Hodgkin’s disease and non-Hodgkin’s lymphoma represents the effects of pretransplant treatment, or results from transplant conditioning and/or stem cell priming,” Dr. Krishnan said.

City of Hope researchers followed 612 patients (median age, 39) undergoing autologous transplants for lymphoma. Twenty-two patients developed morphologic evidence of therapy-related leukemia post-transplant.

Compared with a control group matched for disease and length of follow-up, there were no significant links between the development of leukemia and age at transplant, exposure to pretransplant alkylating agents, prior local radiation, or transplant conditioning regimens.

However, Dr. Krishnan said, stem cell priming with high-dose etoposide was independently associated with increased risk of leukemia with genetic abnormalities (11q23/21q22).

In the cohort study, patients who received PBSCs were more likely to develop myelodysplasia or AML than patients who received bone marrow alone or bone marrow and peripheral blood stem cells.

“We need prospective studies with more sensitive biomarkers from the time of diagnosis in order to determine the sequence of events that ultimately leads to therapy-related leukemia,” Dr. Krishnan concluded.

Articles in this issue

Paclitaxel Plus Mitoxantrone for Poor-Prognosis Breast Cancer
Overview Shows Raloxifene Reduces Breast Cancer Incidence in Postmenopausal Women
Faslodex, Pure Antiestrogen, Studied in Tamoxifen-Resistant Breast Cancer
LHRH Agonist Plus Tamoxifen Improves Outcome in Young Metastatic Patients
Pros and Cons of Different Approaches to Chemoradiation
Less Cardiotoxicity With Liposomal Doxorubicin

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Related Content

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent with IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 12th 2025
Article

At World GU 2025, experts discussed forming treatment strategies for patients with variant histologies across prostate, bladder, and kidney cancer.

Optimizing Care Planning for Variant Histology Populations at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Bradley G. Somer, MD
September 12th 2025
Podcast

In all 9 patients treated with vobramitamab duocarmazine, no objective responses were reported.

Vobramitamab Duocarmazine Does Not Achieve Responses in R/R ES-SCLC

Tim Cortese
September 12th 2025
Article

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 12th 2025
Podcast

Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC

Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC

Ariana Pelosci
September 12th 2025
Article

We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.

Evaluating the Proximity and Impact of a Cure in Multiple Myeloma

Tim Cortese
September 12th 2025
Article
Related Content

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent with IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 12th 2025
Article

At World GU 2025, experts discussed forming treatment strategies for patients with variant histologies across prostate, bladder, and kidney cancer.

Optimizing Care Planning for Variant Histology Populations at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Bradley G. Somer, MD
September 12th 2025
Podcast

In all 9 patients treated with vobramitamab duocarmazine, no objective responses were reported.

Vobramitamab Duocarmazine Does Not Achieve Responses in R/R ES-SCLC

Tim Cortese
September 12th 2025
Article

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 12th 2025
Podcast

Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC

Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC

Ariana Pelosci
September 12th 2025
Article

We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.

Evaluating the Proximity and Impact of a Cure in Multiple Myeloma

Tim Cortese
September 12th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.